NOVATO, Calif. (AP) — NOVATO, Calif. (AP) — Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $133.4 million in its fourth quarter.
On a per-share basis, the Novato, California-based company said it had a loss of $1.39.
The results did not meet Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.24 per share.
The biotechnology company posted revenue of $164.9 million in the period, which topped Street forecasts. Five analysts surveyed by Zacks expected $163.2 million.
For the year, the company reported a loss of $569.2 million, or $6.29 per share. Revenue was reported as $560.2 million.
Ultragenyx expects full-year revenue in the range of $640 million to $670 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。